Acute kidney injury occurs with kidney transplantation and too frequently progresses to the
clinical diagnosis of delayed graft function (DGF). Poor kidney function in the first week of …

Background Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for
prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has …

Background Induction therapy reduces the frequency of acute rejection and delayed graft
function after transplantation. A rabbit antithymocyte polyclonal antibody or basiliximab, an …

Context Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute
rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects …

Background Renal transplantation is the standard of care for patients with end-stage renal
disease. Although maintenance immunosuppression with calcineurin inhibitors yields …

Background Standard practice for immunosuppressive therapy after renal transplantation is
quadruple therapy using antibody induction, low-dose tacrolimus, mycophenolate mofetil …

The evolution of immunosuppression for organ transplantation has reduced the incidence of
acute graft rejection but has increased the risk for infection and virally mediated malignancie …

Antilymphocyte therapies are widely used for immunosuppression in solid organ
transplantation. These agents have varied mechanisms of action, with resulting differences …

Two prospective, randomized studies evaluated everolimus 1.5 vs. 3 mg/day with steroids
and low-exposure cyclosporine (CsA)(C 2 monitoring) in de novo renal transplant patients …

Background. Interleukin 2 receptor antagonists (IL-2Ra) are increasingly used to treat renal
transplant recipients. This study aims to systematically identify and summarize the effects of …